Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of...
| Author | |
|---|---|
| Abstract |
:
Dysglycaemia defined as type 2 diabetes (T2DM) and impaired glucose tolerance (IGT), increases the risk of cardiovascular disease (CVD). The negative impact is more apparent in the presence of hypertension and/or dyslipidaemia. Thus, it seems reasonable to screen for dysglycaemia in patients treated for hypertension and/or dyslipidaemia. A simple screening algorithm would enhance the adoption of such strategy in clinical practice. |
| Year of Publication |
:
2018
|
| Journal |
:
Cardiovascular diabetology
|
| Volume |
:
17
|
| Issue |
:
1
|
| Number of Pages |
:
21
|
| Date Published |
:
2018
|
| URL |
:
https://cardiab.biomedcentral.com/articles/10.1186/s12933-018-0665-4
|
| DOI |
:
10.1186/s12933-018-0665-4
|
| Short Title |
:
Cardiovasc Diabetol
|
| Download citation |
